BioXcel Therapeutics (BTAI) Prices 4M Share Common Offering at $50/Sh

BioXcel Therapeutics, Inc. (NASDAQ: BTAI) today announced the pricing of an underwritten public offering of 4,000,000 shares of common stock at a public offering price of $50.00 per share. In addition, certain selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the public offering price, less underwriting discounts and commissions. Gross proceeds to BTI from the offering are expected to be $200 million, before deducting underwriting discounts and commissions and offering expenses. The Company will not receive any of the proceeds from any sale of shares in this offering by the selling stockholders.

BofA Securities, Goldman Sachs & Co. LLC, Jefferies, Guggenheim Securities and SunTrust Robinson Humphrey are acting as book-running managers for the offering. The offering is expected to close on or about July 31, 2020, subject to customary closing conditions.

You May Also Be Interested In

• Alexandria Real Estate prices $1B junior subordinated notes due 2057
• Silence Therapeutics prices $175 million public offering at $13.50 per ADS
• Savers Value Village launches secondary offering of 15M shares